The Role of Androgen Receptor Signaling in Ovarian Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2019 Feb 23

PMID 30791431

Citations 33

Authors

Taichi Mizushima

Hiroshi Miyamoto

Affiliations

Soon will be listed here.

Abstract

Emerging evidence has suggested that androgen receptor signaling plays an important role in ovarian cancer outgrowth. Specifically, androgen receptor activation appears to be associated with increased risks of developing ovarian cancer and inducing tumor progression. However, conflicting findings have also been reported. This review summarizes and discusses the available data indicating the involvement of androgens as well as androgen receptor and related signals in ovarian carcinogenesis and cancer growth. Although the underlying molecular mechanisms for androgen receptor functions in ovarian cancer remain far from being fully understood, current observations may offer effective chemopreventive and therapeutic approaches, via modulation of androgen receptor activity, against ovarian cancer. Indeed, several clinical trials have been conducted to determine the efficacy of androgen deprivation therapy in patients with ovarian cancer.

Citing Articles

Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date review.

Leone A, Bonadonna S, Cassani C, Barcellini A, Sirico M, Tagliaferri B BMJ Oncol. 2025; 3(1):e000330.

PMID: 39886120 PMC: 11235029. DOI: 10.1136/bmjonc-2024-000330.

The androgen clock is an epigenetic predictor of long-term male hormone exposure.

Sugrue V, Prescott M, Glendining K, Bond D, Horvath S, Anderson G Proc Natl Acad Sci U S A. 2025; 122(3):e2420087121.

PMID: 39805019 PMC: 11760496. DOI: 10.1073/pnas.2420087121.

miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.

Wang X, Woo H, Wei M, Gibson S, Miranda M, Rush D Sci Rep. 2024; 14(1):29937.

PMID: 39622842 PMC: 11611913. DOI: 10.1038/s41598-024-80173-z.

Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.

Dotto G, Buckinx A, Ozdemir B, Simon C Nat Rev Cancer. 2024; 25(2):93-108.

PMID: 39587300 DOI: 10.1038/s41568-024-00772-w.

GWAS and 3D chromatin mapping identifies multicancer risk genes associated with hormone-dependent cancers.

Rivera I, French J, Bitar M, Sivakumaran H, Nair S, Kaufmann S PLoS Genet. 2024; 20(11):e1011490.

PMID: 39585897 PMC: 11627375. DOI: 10.1371/journal.pgen.1011490.

References

Nagle C, Chenevix-Trench G, Webb P, Spurdle A . Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes. Cancer Lett. 2006; 251(1):96-104. DOI: 10.1016/j.canlet.2006.11.011. View

Palmieri C, Gojis O, Rudraraju B, Stamp-Vincent C, Wilson D, Langdon S . Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer. 2013; 108(10):2039-44. PMC: 3670494. DOI: 10.1038/bjc.2013.199. View

Martins F, de Santiago I, Trinh A, Xian J, Guo A, Sayal K . Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 2015; 15(12):526. PMC: 4268857. DOI: 10.1186/s13059-014-0526-8. View

Stephenson S, Verity K, Ashworth L, Clements J . Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem. 1999; 274(33):23210-4. DOI: 10.1074/jbc.274.33.23210. View

Sawada M, Terada N, Wada A, Mori Y, Yamasaki M, Saga T . Estrogen- and androgen-responsive growth of human ovarian adenocarcinoma heterotransplanted into nude mice. Int J Cancer. 1990; 45(2):359-63. DOI: 10.1002/ijc.2910450225. View

Wang R, Chang H, Kao S, Kao C, Wu Y, Yeh S . Abnormal mitochondrial function and impaired granulosa cell differentiation in androgen receptor knockout mice. Int J Mol Sci. 2015; 16(5):9831-49. PMC: 4463620. DOI: 10.3390/ijms16059831. View

Dizon D, Tejada-Berges T, Koelliker S, Steinhoff M, Granai C . Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest. 2006; 62(4):226-8. DOI: 10.1159/000094097. View

Park B, Grisham R, den Hollander B, Thapi D, Berman T, de Stanchina E . Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer. Cancer Invest. 2016; 34(10):517-520. PMC: 5546102. DOI: 10.1080/07357907.2016.1242598. View

Kuper H, Cramer D, Titus-Ernstoff L . Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status?. Cancer Causes Control. 2002; 13(5):455-63. DOI: 10.1023/a:1015751105039. View

10.

Slotman B, Rao B . Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Lett. 1989; 45(3):213-20. DOI: 10.1016/0304-3835(89)90080-3. View

11.

Sun P, Wei L, Luo M, Liu G, Wang J, Mustea A . The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2006; 130(2):249-57. DOI: 10.1016/j.ejogrb.2006.01.028. View

12.

van Doorn H, Burger C, van der Valk P, Bonfrer H . Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. J Clin Pathol. 2000; 53(3):201-5. PMC: 1731160. DOI: 10.1136/jcp.53.3.201. View

13.

Butler M, Ricciardelli C, Tilley W, Hickey T . Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Horm Cancer. 2013; 4(3):154-64. PMC: 10358082. DOI: 10.1007/s12672-013-0135-0. View

14.

Blaakaer J, Hogdall C, Hording U, Bennett P, Daugaard S, Bock J . Hormonal factors and prognosis in epithelial ovarian cancer: a multivariate analysis. Eur J Obstet Gynecol Reprod Biol. 1993; 51(1):21-7. DOI: 10.1016/0028-2243(93)90186-g. View

15.

Kuhnel R, de Graaff J, Rao B, STOLK J . Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987; 26(3):393-7. DOI: 10.1016/0022-4731(87)90106-3. View

16.

Ludwig A, Murawska M, Panek G, Timorek A, Kupryjanczyk J . Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer. 2009; 16(3):1005-16. DOI: 10.1677/ERC-08-0135. View

17.

Nam R, Elhaji Y, Krahn M, Hakimi J, Ho M, Chu W . Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol. 2000; 164(2):567-72. View

18.

Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C . A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer. 2007; 110(11):2448-56. DOI: 10.1002/cncr.23072. View

19.

van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H . Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138(3):634-9. DOI: 10.1016/j.ygyno.2015.06.032. View

20.

Li A, Scoles D, Armstrong K, Karlan B . Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol. 2008; 109(2):220-5. DOI: 10.1016/j.ygyno.2008.02.010. View